SCHEMBL6868302

SCHEMBL6868302

NC1(C(=O)OCc2ccccc2)CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
DDB1 Q16531 1/20 0.48
CRBN Q96SW2 1/20 0.48
ALDH1A1 P00352 3/20 0.45
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CTSC P53634 1/20 0.43
AKR1B10 O60218 1/20 0.42
AKR1B1 P15121 1/20 0.42
CA4 P22748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3028267 0.91 DDB1 (0.46) KMT2AMEN1NPSR1DDB1CRBN
SCHEMBL2542693 0.89 DDB1 (0.54) KMT2AMEN1DDB1CRBNALDH1A1
Hydrochloric Acid SCHEMBL2805409 0.87 DDB1 (0.52) KMT2AMEN1DDB1CRBNALDH1A1
SCHEMBL3192 0.86 DDB1 (0.51) KMT2ADDB1CRBNALDH1A1LMNA
SCHEMBL1144346 0.86 DDB1 (0.51) KMT2ADDB1CRBNALDH1A1LMNA
SCHEMBL5358863 0.84 KMT2A (0.54) KMT2AMEN1NPSR1DDB1CRBN
SCHEMBL551405 0.84 DDB1 (0.50) KMT2ADDB1CRBNALDH1A1LMNA
Hydrochloric Acid SCHEMBL1809434 0.84 DDB1 (0.50) KMT2ADDB1CRBNALDH1A1LMNA
SCHEMBL1841706 0.84 DDB1 (0.50) KMT2ADDB1CRBNALDH1A1LMNA
SCHEMBL1966881 0.83 KMT2A (0.52) KMT2AMEN1NPSR1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504537-B2 Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-03-17 US disclosed
US-7504537-B2 Hydroxamic acid derivative and MMP inhibitor containing the same as active ingredient DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-03-17 US disclosed
EP-1068180-B1 PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTENASE INHIBITORS PFIZER PROD INC (US) 2004-12-15 EP disclosed
EP-0949245-B1 Process for alkylating hindered sulfonamides PFIZER PROD INC (US) 2001-10-04 EP disclosed
US-6288246-B1 REACTION OF HYDROXYLAMINE WITH ALKYLSILYL HALIDE, HYDROLYSIS WITH ACID PFIZER INC 2001-09-11 US disclosed
CN-1296474-A Alkylation of hindered sulfonamides for the preparation of matrix metalloproteinase inhibitors PFIZER PROD INC (US) 2001-05-23 CN disclosed
US-6229025-B1 MICHAEL ADDITION TO PROPIOLATES PFIZER INC 2001-05-08 US disclosed
EP-1068180-A1 PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTENASE INHIBITORS Pfizer Products Inc. (US) 2001-01-17 EP disclosed
US-6114568-A Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors PFIZER INC. (US) 2000-09-05 US disclosed
WO-1999052862-A1 PROCESS FOR ALKYLATING HINDERED SULFONAMIDES USEFUL IN THE PRODUCTION OF MATRIX METALLOPROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 1999-10-21 WO disclosed
CN-1232023-A Process for preparing hydroxamic acids PFIZER PROD INC (US) 1999-10-20 CN disclosed
EP-0949244-A2 Process for preparing hydroxamic acids Pfizer Products Inc. (US) 1999-10-13 EP disclosed
EP-0949245-A1 Process for alkylating hindered sulfonamides Pfizer Products Inc. (US) 1999-10-13 EP disclosed